Hot Stocks BeiGene presents Phase 3 data on tislelizumab and pamiparib » BeiGene $263.10 / +7.97 (+3.12%) BGNE BeiGene announced the… BeiGene announced the first reported data from Rationale 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer, or NSCLC, and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer at the European Society for Medical Oncology Virtual Congress 2020. Tislelizumab in combination with pemetrexed and platinum chemotherapy demonstrated "encouraging" results among advanced NSCLC patients with non-squamous histology, including a median progression-free survival of 9.7 months and an overall response rate of 57.4%. RATIONALE 304 is a Phase 3 clinical trial of tislelizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with stage IIIB or stage IV non-squamous NSCLC. The trial achieved the primary endpoint of progression-free survival with a median of 9.7 months in Arm A, vs. 7.6 months in the chemotherapy alone Arm B; higher objective response rate and disease control rate were achieved in patients who received tislelizumab in combination with chemotherapy - 57.4% and 89.2% in Arm A vs. 36.9% and 81.1% in Arm B; longer duration of response in patients who received tislelizumab in combination with chemotherapy, with a median of 8.5 months in Arm A vs. 6.0 months in Arm B; treatment of tislelizumab in combination with platinum and pemetrexed was generally well-tolerated, with no new safety signals identified. All patients in Arm A and 99.1% of patients in Arm B experienced at least one treatment-emergent adverse event; nine patients experienced a fatal TEAE. Preliminary results presented at ESMO 2020 were from a Phase 2 dose-expansion portion of a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer enrolled a total of 113 patients in China. Pamiparib was generally tolerated, consistent in patients with PSOC and PROC, and similar to other PARP inhibitors; most common TEAEs included anemia, nausea, decreased neutrophil count and others. No myelodysplastic syndrome or significant complications potentially related to hematologic AEs were reported in the trial. Show Hide Related Items >> << Company News

Street Research

Earnings

On The Fly

Events BGNE BeiGene $263.10 / +7.97 (+3.12%) 09/09/20 BeiGene announces Health Canada acceptance, priority review of NDS for BRUKINSA 08/27/20 BeiGene to develop, manufacture Singlomics anti-COVID-19 antibodies 08/24/20 BeiGene enters license, distribution, supply agreement with Bio-Thera Solutions 07/27/20 BeiGene granted priority review for pamiparib NDA BGNE BeiGene $263.10 / +7.97 (+3.12%) 08/07/20 Ladenburg BeiGene price target raised to $268 from $232 at Ladenburg 08/06/20 Piper Sandler BeiGene price target raised to $175 from $165 at Piper Sandler 07/21/20 Baird Assembly Biosciences HBV deal a positive, says Baird 07/20/20 Piper Sandler BeiGene inked smart deal with Assembly, says Piper Sandler BGNE BeiGene $263.10 / +7.97 (+3.12%) 08/06/20 BeiGene reports Q2 EPS ($4.31), consensus ($4.77) BGNE BeiGene $263.10 / +7.97 (+3.12%) 05/04/20 Fly Insider: Five Point, Acadia among week's notable insider trades

On The Fly Fly Intel: After-Hours Movers » Sonoma Pharmaceuticals $7.71 / -0.04 (-0.52%) SNOA J. Alexander's $4.79 / -0.005 (-0.10%) JAX Kezar Life Sciences $5.17 / +0.26 (+5.30%) KZR Ashford Hospitality $1.99 / -0.08 (-3.86%) AHT Idacorp $83.54 / +0.63 (+0.76%) IDA Checkpoint Therapeutics $3.49 / -0.76 (-17.88%) CKPT Windtree Therapeutics $7.08 / +0.46 (+6.95%) WINT Check out this evening's… Open Full Text Show Hide Related Items >> << Company News

Street Research

Earnings

Syndicate

Periodicals

On The Fly

Events

Options WINT

SNOA

KZR

JAX

IDA

CKPT

AHT WINT Windtree Therapeutics $7.08 / +0.46 (+6.95%) 07/20/20 Windtree Therapeutics names John Hamill as CFO, succeeding John Tattory 06/24/20 Windtree Therapeutics: Initial European trial sites activated in AEROSURF study SNOA Sonoma Pharmaceuticals $7.71 / -0.04 (-0.52%) 09/17/20 Sonoma Pharma surges 21.1% after Health Canada authorizes Nanocyn sale 09/17/20 Sonoma, MicroSafe say Health Canada authorized sale of Nanocyn in Canada 09/09/20 Sonoma Pharmaceuticals,Te Arai BioFarma launch Microcyn products in Australia 05/28/20 Sonoma Pharmaceuticals, MicroSafe's Nanocyn approved in COVID-19 prevention KZR Kezar Life Sciences $5.17 / +0.26 (+5.30%) 09/17/20 Kezar Life highlights data from MISSION study during PANLAR 2020 06/03/20 Kezar Life Sciences announces updated results from portion of MISSION trial 05/04/20 Kezar Life Sciences appoints Noreen Henig, MD as Chief Medical Officer 04/09/20 Kezar Life Sciences expects cash to fund company into 3Q22 JAX J. Alexander's $4.79 / -0.005 (-0.10%) 09/17/20 J. Alexander's reports Q3 J. Alexander's/Grill SSS down 9.9% 04/20/20 J. Alexander's enters into cooperation agreement with Ancora Advisors 03/24/20 J. Alexander's announces steps taken to address coronavirus IDA Idacorp $83.54 / +0.63 (+0.76%) 09/17/20 Idacorp raises quarterly cash dividend 6% to 71c per share CKPT Checkpoint Therapeutics $3.49 / -0.76 (-17.88%) 09/17/20 Checkpoint Therapeutics' cosibelimab shows 51.4% response rate in MCSCC 07/27/20 Checkpoint Therapeutics to present cosibelimab interim results 04/21/20 Checkpoint issued U.S. composition of matter patent for cosibelimab AHT Ashford Hospitality $1.99 / -0.08 (-3.86%) 09/17/20 Ashford Hospitality shareholder Cygnus Capital issues letter 07/21/20 Ashford Hospitality falls -17.2% 07/21/20 Ashford Hospitality falls -17.0% 07/20/20 Ashford Hospitality falls -11.1% SNOA

JAX

KZR

AHT

IDA

CKPT

WINT SNOA Sonoma Pharmaceuticals $7.71 / -0.04 (-0.52%) JAX J. Alexander's $4.79 / -0.005 (-0.10%) KZR Kezar Life Sciences $5.17 / +0.26 (+5.30%) 06/04/20 H.C. Wainwright Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright 05/05/20 H.C. Wainwright Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright AHT Ashford Hospitality $1.99 / -0.08 (-3.86%) 06/17/20 Fly Intel: Top five analyst upgrades 06/17/20 DA Davidson Ashford Hospitality upgraded to Neutral from Underperform at DA Davidson 04/06/20 B. Riley FBR Ashford Hospitality downgraded to Neutral from Buy at B. Riley FBR 03/10/20 DA Davidson Ashford Hospitality downgraded to Underperform from Neutral at DA Davidson IDA Idacorp $83.54 / +0.63 (+0.76%) 05/04/20 Sidoti Idacorp upgraded to Buy on valuation at Sidoti 05/04/20 Sidoti Idacorp upgraded to Buy from Neutral at Sidoti 03/18/20 BofA Idacorp upgraded to Buy from Neutral at BofA 11/04/19 BofA Idacorp upgraded to Neutral from Underperform at BofA/Merrill CKPT Checkpoint Therapeutics $3.49 / -0.76 (-17.88%) 06/25/20 Lake Street Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab 04/13/20 B. Riley FBR AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR 12/27/19 Lake Street Checkpoint Therapeutics price target lowered to $8 from $12 at Lake Street 10/17/19 Lake Street Checkpoint Therapeutics shares reflect 'valuation disconnect,' says Lake Street WINT Windtree Therapeutics $7.08 / +0.46 (+6.95%) 06/26/20 Fly Intel: Top five analyst initiations 06/26/20 Ladenburg Windtree Therapeutics initiated with a Buy at Ladenburg KZR

IDA

CKPT KZR Kezar Life Sciences $5.17 / +0.26 (+5.30%) 08/05/20 Kezar Life Sciences reports Q2 EPS (22c), consensus (26c) 05/07/20 Kezar Life Sciences reports Q1 EPS (30c), consensus (38c) IDA Idacorp $83.54 / +0.63 (+0.76%) 07/30/20 Idacorp backs FY20 EPS view of $4.45-$4.65, consensus $4.54 07/30/20 Idacorp reports Q2 EPS $1.19, consensus $1.21 04/30/20 Idacorp backs FY20 EPS view $4.45-$4.65, consensus $4.60 04/30/20 Idacorp reports Q1 EPS 74c, two estimates 80c CKPT Checkpoint Therapeutics $3.49 / -0.76 (-17.88%) 08/05/20 Checkpoint Therapeutics reports Q2 EPS (9c), consensus (9c) 05/06/20 Checkpoint Therapeutics reports Q1 EPS (6c), consensus (13c) AHT AHT Ashford Hospitality $1.99 / -0.08 (-3.86%) 08/04/20 SEC investigating Texas hotelier Monty Bennett's companies, WSJ reports SNOA KZR SNOA Sonoma Pharmaceuticals $7.71 / -0.04 (-0.52%) 09/09/20 Fly Intel: After-Hours Movers 05/28/20 Fly Intel: After-Hours Movers KZR Kezar Life Sciences $5.17 / +0.26 (+5.30%) 06/08/20 Fly Intel: Pre-market Movers 06/04/20 Fly Intel: Pre-market Movers 06/03/20 Fly Intel: After-Hours Movers KZR KZR Kezar Life Sciences $5.17 / +0.26 (+5.30%) 05/28/20 Thirteen new option listings and four option delistings on May 28th



Hot Stocks Air Lease announces delivery of one new Airbus A350-1000 jet » Airbus $0.00 / + (+0.00%) EADSY Air Lease $32.65 / -0.3801 (-1.15%) AL Air Lease Corporation… Air Lease Corporation (AL) announced the delivery of one new Airbus (EADSY) A350-1000 aircraft on long-term lease to Virgin Atlantic. Powered by Trent XWB-97 engines, this aircraft is the first of four A350-1000s confirmed to deliver to the airline from ALC's order book with Airbus. "We are pleased to announce this first new A350-1000 aircraft delivery to Virgin Atlantic today," said Steven F. Udvar-Hazy, Executive Chairman of Air Lease Corporation. "Our A350-1000s will replace Virgin Atlantic's Boeing 747 aircraft on routes from London across the Atlantic to modernize the airline's long-haul fleet." Show Hide Related Items >> << Company News

Street Research

Earnings

Periodicals

On The Fly

Events EADSY

AL EADSY Airbus $0.00 / + (+0.00%) 09/08/20 Airbus delivers 39 aircraft in August 09/01/20 Triumph, Airbus extend Asia repair station services partnership 09/01/20 L3Harris selected to build space antenna by Airbus Defence and Space 08/03/20 Triumph Group to sell composites operations to Arlington Capital Partners AL Air Lease $32.65 / -0.3801 (-1.15%) 07/08/20 Air Lease fleet comprised of 301 owned, 81 managed aircraft as of June 30 06/24/20 Air Lease announces lease placement of Airbus A319 jets with HiSky Moldova 06/18/20 Air Lease announces delivery of new A320-200neo jet to Atlantic Airways 06/09/20 Air Lease announces lease placement for a used Airbus A320 with HiSky Moldova EADSY

AL EADSY Airbus $0.00 / + (+0.00%) 09/17/20 Credit Suisse Airbus price target raised to EUR 106 from EUR 78 at Credit Suisse 09/09/20 Fly Intel: Top five analyst downgrades 09/09/20 Morgan Stanley Airbus downgraded to Equal Weight from Overweight at Morgan Stanley 08/10/20 JPMorgan Airbus price target lowered to EUR 50 from EUR 54 at JPMorgan AL Air Lease $32.65 / -0.3801 (-1.15%) 06/01/20 BofA AerCap downgraded to Neutral from Buy at BofA 05/26/20 JPMorgan JPMorgan upgrades Fly Leasing with stock rally lagging peers 05/11/20 Deutsche Bank Air Lease price target lowered to $36 from $45 at Deutsche Bank EADSY

AL EADSY Airbus $0.00 / + (+0.00%) 07/30/20 Airbus reports H1 EPS EUR (1.01) vs. EUR 2.25 last year 07/22/20 Kaiser Aluminum sees revenue from commercial aerospace/defense lower in 2H 07/22/20 Kaiser Aluminum reports Q2 EPS 46c, consensus (4c) 04/29/20 Airbus reports Q1 EPS (EUR 0.61) vs. EUR 0.05 a year ago AL Air Lease $32.65 / -0.3801 (-1.15%) 08/06/20 Air Lease reports Q2 adjusted EPS $1.71, consensus $1.06 05/07/20 Air Lease says 'cannot reasonably estimate' financial conditions, results 05/07/20 Air Lease reports Q1 adjusted EPS $1.61, consensus $1.22 EADSY

AL EADSY Airbus $0.00 / + (+0.00%) 09/02/20 Qatar Airways reaches delivery delay pact with Airbus, Reuters reports 08/06/20 Airbus investors sue in U.S. over claims of disclosure fraud, Reuters reports 07/30/20 Airbus doesn't plan to increase aircraft production until around 2022, WSJ says 07/26/20 Finished airplanes pile up at Boeing, Airbus, WSJ reports AL Air Lease $32.65 / -0.3801 (-1.15%) 06/04/20 SMBC Aviation CEO cautions of difficulty for aircraft leasing industry, FT says EADSY EADSY Airbus $0.00 / + (+0.00%) 07/08/20 Spirit downgrade, Nikola upgrade among today's top calls on Wall Street 06/30/20 Fly Intel: Wall Street's top stories for Tuesday 06/26/20 Boeing, Airbus downgrades among today's top calls on Wall Street 06/20/20 Week in Review: How Trump's policies moved stocks

Earnings Steel Dynamics sees Q3 adjusted EPS 46c-50c, consensus 38c » Steel Dynamics $31.26 / +0.81 (+2.66%) STLD Third quarter 2020… Third quarter 2020 earnings from the company's steel operations are expected to be lower than sequential second quarter results, due to metal spread compression more than offsetting increased shipments driven by improved automotive and strong construction demand. Average realized quarterly flat roll steel product pricing is expected to decrease during the quarter based in part on lagging price-indexed contracts, offsetting the benefit of lower average scrap costs. However, flat roll steel pricing has stabilized and improved during the second half of the third quarter, supported by customer demand and raw material pricing. As domestic steel production improved in the third quarter from the trough experienced in the sequential second quarter, ferrous scrap demand also strengthened. Based on significantly higher scrap shipments, third quarter earnings from the company's metals recycling operations are expected to be meaningfully better than sequential second quarter results. Construction continues to show its resiliency. The customer order backlog for the company's steel fabrication platform remains strong, and customers are optimistic concerning non-residential construction projects. Third quarter 2020 earnings from the company's steel fabrication operations are expected to be at, or near, record results, based on anticipated record shipments and margin expansion, as product pricing is expected to improve while steel input costs decrease. Show Hide Related Items >> << Company News

Street Research

Earnings

Periodicals

On The Fly

Options STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 07/20/20 Steel Dynamics CEO: We remain in a position of strength 07/07/20 Air Liquide in supply pact with Steel Dynamics for EAF in Sinton, Texas 04/20/20 Steel Dynamics up over 4% at $23.50 after Q1 earnings beat 04/20/20 Steel Dynamics CEO says domestic steel orders slowed considerably STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 07/29/20 Deutsche Bank Steel Dynamics price target raised to $31 from $27 at Deutsche Bank 06/19/20 BMO Capital Steel Dynamics price target raised to $29 from $24 at BMO Capital 06/08/20 Citi Commercial Metals downgraded at Citi on valuation, scrap costs 05/13/20 KeyBanc Steel Dynamics downgraded to Sector Weight from Overweight at KeyBanc STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 07/20/20 Steel Dynamics reports Q2 adjusted EPS 47c, consensus 35c 07/20/20 Notable companies reporting after market close 06/18/20 Steel Dynamics sees Q2 adjusted EPS 40c-44c, consensus 26c 04/20/20 Steel Dynamics reports Q1 EPS 88c, consensus 79c STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 08/27/20 Nucor, US Steel raise sheet prices by $40/st, Argus says 06/22/20 U.S. Supreme Court declines to hear appeal to steel tariffs, Reuters reports 05/20/20 Iron ore prices jump amid Brazil coronavirus mining disruption, WSJ says 04/20/20 Steel companies' slump seen getting worse, WSJ reports STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 06/27/20 Week in review: How Trump's policies moved stocks 06/18/20 Fly Intel: After-Hours Movers 04/21/20 Fly Intel: Pre-market Movers 04/20/20 Fly Intel: After-Hours Movers STLD Steel Dynamics $31.26 / +0.81 (+2.66%) 04/20/20 Steel Dynamics options imply 12.6% move in share price post-earnings